Turki Saeed Alkahtani
Turki Saeed Alkahtani has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahad Abdulaziz Alruhaymi
College of Medicine , King Saud bin Abdulaziz University for Health Sciences , Riyadh , Saudi Arabia , ksau-hs.edu.sa
1 shared publication - Ahmed Ayed N. Alanazi
College of Medicine and Health Sciences , Arabian Gulf University , Manama , Bahrain , agu.edu.bh
1 shared publication - Ahmed N. Alqefari
College of Medicine and Surgery , Qassim University , Qassim , Saudi Arabia , qu.edu.sa
1 shared publication - Alanoud Abdullah Al Daej
College of Medicine , Alfaisal University , Riyadh , Saudi Arabia , alfaisal.edu
1 shared publication - Aliyah Abdulmohsen Alabdulqader
College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
1 shared publication - Elissa Nassif
Dermatology Department , Lebanese University , Beirut , Lebanon , ul.edu.lb
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 3648230
Topical Cholesterol and Statin Therapy for Porokeratosis: A Systematic Review and Exploratory Meta‐Analysis
Background: Porokeratosis comprises a group of clinically diverse keratinization disorders unified by the cornoid lamella and increasingly understood through alterations in the mevalonate/cholesterol biosynthesis pathway, including germline variants, somatic second‐hit events, clonal mosaicism, and emerging epigenetic mechanisms. These biological insights support investigation of pathogenesis‐directed topical statin‐based therapy, with or without cholesterol supplementation. Aim: This systematic review evaluated the reported clinical improvement, safety, and comparative evidence of topical cholesterol/statin combination therapy versus topical statin monotherapy for porokeratosis. Methods: PubMed, Scopus, Web of Science, and Cochrane Library were searched through January 2026. Two independent reviewers screened studies and extracted data on study design, porokeratosis subtype, treatment formulation, clinical outcomes, and adverse events. Because the evidence base consisted largely of small uncontrolled reports with heterogeneous outcome definitions, quantitative summaries were considered exploratory and were interpreted cautiously. Results: Thirteen studies including 89 patients were included. Most studies were case reports or case series, with limited controlled evidence. Published uncontrolled reports generally described clinical improvement after topical cholesterol/statin therapy, including improvement in erythema and lesion morphology; however, these findings are subject to substantial selection, reporting, and publication bias. Safety data suggested that adverse events were usually mild and local, including application‐site discomfort, transient pruritus, erythema, dryness, or eczematous reactions. In the available controlled studies comparing combination therapy with topical statin monotherapy, no statistically significant difference was detected in clinical improvement or severity‐score change, although confidence intervals were wide and the analyses were underpowered. Conclusion: Topical cholesterol/statin therapy remains a biologically plausible and clinically promising approach for porokeratosis, but larger standardized randomized trials are required to define its comparative effectiveness, optimal formulation, and long‐term safety.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 3648230
Open AccessTopical Cholesterol and Statin Therapy for Porokeratosis: A Systematic Review and Exploratory Meta‐Analysis
Background: Porokeratosis comprises a group of clinically diverse keratinization disorders unified by the cornoid lamella and increasingly understood through alterations in the mevalonate/cholesterol biosynthesis pathway, including germline variants, somatic second‐hit events, clonal mosaicism, and emerging epigenetic mechanisms. These biological insights support investigation of pathogenesis‐directed topical statin‐based therapy, with or without cholesterol supplementation. Aim: This systematic review evaluated the reported clinical improvement, safety, and comparative evidence of topical cholesterol/statin combination therapy versus topical statin monotherapy for porokeratosis. Methods: PubMed, Scopus, Web of Science, and Cochrane Library were searched through January 2026. Two independent reviewers screened studies and extracted data on study design, porokeratosis subtype, treatment formulation, clinical outcomes, and adverse events. Because the evidence base consisted largely of small uncontrolled reports with heterogeneous outcome definitions, quantitative summaries were considered exploratory and were interpreted cautiously. Results: Thirteen studies including 89 patients were included. Most studies were case reports or case series, with limited controlled evidence. Published uncontrolled reports generally described clinical improvement after topical cholesterol/statin therapy, including improvement in erythema and lesion morphology; however, these findings are subject to substantial selection, reporting, and publication bias. Safety data suggested that adverse events were usually mild and local, including application‐site discomfort, transient pruritus, erythema, dryness, or eczematous reactions. In the available controlled studies comparing combination therapy with topical statin monotherapy, no statistically significant difference was detected in clinical improvement or severity‐score change, although confidence intervals were wide and the analyses were underpowered. Conclusion: Topical cholesterol/statin therapy remains a biologically plausible and clinically promising approach for porokeratosis, but larger standardized randomized trials are required to define its comparative effectiveness, optimal formulation, and long‐term safety.